| http://www.w3.org/ns/prov#value | - The CHARISMA trial [71] demonstrated that dual antiplateltes (ASA plus clopidogrel) were more effective than ASA alone especially in patients with clinically evident cardiovascular disease (i.e., in secondary prevention CV death, MI, and stroke) rather than in patients with high risk profile but not established atherothrombotic disease (i.e., primary prevention).
|
